Propylene glycol (PG) has been used for decades as a highly functional pharmaceutical and consumer health excipient. It is valued as a solvent, co-solvent, humectant and carrier, particularly in oral liquids, topical products and selected parenteral formulations. The European Medicines Agency describes propylene glycol as a clear, colourless, hygroscopic liquid, miscible with water, and notes its use across multiple dosage forms and functions, including as a humectant in topical products (EMA, 2017). Like many long-established excipients, its history is not one of sudden concern, but of evolving scrutiny as expectations around quality, transparency and trusted excipients become more demanding.

The current IngredAgent signal around propylene glycol is best understood as a watchlist signal, not a simple safe/unsafe narrative. In IngredAgent’s INGRA intelligence, propylene glycol is tracked within the Glycerin / Propylene Glycol cluster, which is in the High-alert watchlist range driven mainly by APAC-linked quality vigilance and contamination-related concerns. In the March 2026 cycle, the cluster remained High but stable, with a March Mean Weighted Score of 2.95 and a stable quality-vigilance interpretation (IngredAgent, 2026).

The strongest global driver is not traditional toxicological concern, but signal propagation from contamination events involving high-risk liquid excipients. FDA’s 2023 guidance specifically named propylene glycol, glycerin, maltitol solution, hydrogenated starch hydrolysate and sorbitol solution among high-risk drug components requiring attention for possible diethylene glycol and ethylene glycol contamination (FDA, 2023). WHO alerts on contaminated syrup and suspension medicines have also reinforced global vigilance around oral liquid dosage forms and excipient supply-chain quality (WHO, 2023). This is precisely the kind of pattern IngredAgent is designed to detect: a quality signal begins regionally, is amplified by major regulatory authorities, then spreads into broader global expectations around supplier verification, testing and formulation stewardship.

IngredAgent’s Score module translates this intelligence into product-level decision support. A formulation containing propylene glycol is not automatically treated as problematic. Instead, Score evaluates the excipient in context: route of administration, official label language, INGRA watchlist status, Human Health and Ecosystem Health inputs, and whether any regulatory warnings or high-risk overlays apply. This allows teams to distinguish between a formulation where PG is functionally justified and well controlled, versus one where it contributes materially to broader formulation stewardship considerations (IngredAgent, 2025a).

The Design module then turns insight into action. Where a client chooses to reduce reliance on propylene glycol, IngredAgent’s Sustainability by Design workflow first confirms the role of PG in the formulation – solvent, co-solvent, humectant, preservative support or flavour carrier – then proposes alternatives based on functional equivalence. For aqueous oral liquids for example, preferred options may include xylitol, sorbitol or maltitol systems; sodium lactate or polyol blends for humectancy; hydroxypropyl betadex/cyclodextrin complexation for solubilisation; reformulated flavour/carrier systems; and xanthan gum, hydroxyethyl cellulose or sodium alginate to rebuild rheology. These are not presented as one-for-one substitutions; the Design workflow evaluates stability, solubility, viscosity, preservative performance, sensory impact, regulatory status and supplier robustness before proposing a DoE-ready remediation plan (IngredAgent, 2025b).

Propylene glycol therefore illustrates IngredAgent’s full value proposition: Intel detects the global signal, Score shows whether it matters in a specific formulation, and Design provides a structured pathway to reformulate where appropriate. In a market increasingly shaped by trusted excipients, this shifts organisations from reactive issue management to proactive formulation stewardship. Propylene glycol nevertheless remains a globally accepted and widely used pharmaceutical excipient when manufactured, tested and controlled according to applicable quality standards and pharmacopoeial requirements. IngredAgent’s Score module translates this intelligence into product-level decision support.